Pamphlets detailing the warning signs associated with heart disease may soon end up in an unexpected location: your child's pediatrician's office. According to new research from the Centers for Disease Control and Prevention (CDC), one in five American teens has at least one risk factor for developing heart disease in adulthood. With heart health front-and-center this month in honor of American Heart Month, most media coverage will focus on at-risk adults. But that's a mistake according to Sarah Wally, a dietitian with the National Association for Margarine Manufacturers. "Although heart disease is typically diagnosed in adulthood, its roots often begin in childhood, " says Wally.
If you think heart disease is a disease of the middle aged, think again. Experts recommend that cholesterol screening should begin as early as 20 years of age because it is a key indicator of heart-attack risk, and should be rechecked at least once every five years. Atherosclerosis begins early, says Dr. Anand Rohatgi, cardiologist with UT Southwestern Medical Center's program in preventive cardiology. Even young adults and teens can show evidence of atherosclrosis, or hardening of the arteries. If early screening reveals low levels of good cholesterol (HDL) or moderately high levels of the bad cholesterol (LDL), counseling is provided to help modify lifestyles.
By considering molecular-level events on a broader scale, researchers now have a clearer, if more complicated, picture of how one class of immune cells goes wrong when loaded with cholesterol. The findings reported in the February 3rd issue of Cell Metabolism, a Cell Press publication, show that, when it comes to the development of atherosclerosis and heart disease, it's not about any one bad actor - it's about a network gone awry. The new findings also highlight a pretty remarkable thing, Heinecke says: "Despite 30 years of study, we still don't know how cholesterol causes heart disease." But, with the new findings, scientists are getting closer.
The team identified beta-sitosterol - a steroid that can inhibit the absorption of cholesterol in the intestine - as the main constituent of pomegranate seed extract. The research suggests that pomegranate extract could be used as a natural stimulant to encourage the uterus to contract during labour. Pomegranate juice is thought to have a number of health benefits, from lowering cholesterol and blood pressure to protecting against some cancers, but until now there has been no evidence to demonstrate its effects on the uterus. Researchers investigated pomegranate seed extract - more highly concentrated than pomegranate juice - and its effect on uterine smooth muscle samples.
Siemens Healthcare Diagnostics has introduced concentrated Cholesterol, the 15th ADVIA® Chemistry reagent in concentrated format. ADVIA Chemistry concentrated reagents offer up to 3060 tests per wedge, whilst still giving identical results to the conventional ADVIA non-concentrated reagents. This increased capacity is of particular benefit to high throughput laboratories, extending processing time and increasing laboratory productivity. Concentrated reagent wedges liberate space on the reagent carousel, allowing laboratories to extend testing repertoire. This consolidation of tests onto high throughput routine ADVIA Chemistry reduces turnaround times and increases the laboratory's processing efficiency.
Research Published By Standard Process Inc. Scientists About The Effects Of Dietary Intervention On Cholesterol Levels
In collaboration with the scientists in the Department of Animal Sciences at the University of Wisconsin-Madison, Standard Process scientists have published a study examining the effects of nutritional supplement ingredients on cholesterol levels in Rapacz familial hypercholesterolemic swine or FH swine. Findings of this study were reported in the Journal of Medicinal Food. The scientists designed the study to compare nutritional components found in foods and supplements (pectin, polyphenols, and phytosterols) with a first-generation cholesterol medication (Lovastatin) to examine serum cholesterol levels in swine with a genetically altered tendency toward high cholesterol.
Statins have proven highly effective at lowering cholesterol. Typically, a treat-to-target approach, which means treating to a target cholesterol level, is taken with statin therapy. However, some experts believe that a tailored approach that uses different dosages based on pateints' risk for cardiovascular disease may be a better strategy for reducing the risk of coronary artery disease. Researchers developed a computer simulation to compare two treatment approaches at the population level-- giving fixed doses of statins on the basis of a person's five-year coronary artery disease risk (tailored treatment), or increasing statin doses to achieve particular lipid level targets (treat-to-target).
A new study by the University of Michigan Medical School and VA Ann Arbor Health System challenges the medical thinking that the lower the cholesterol, the better. Tailoring treatment to a patient's overall heart attack risk, by considering all their risk factors, such as age, family history, and smoking status, was more effective, and used fewer high-dose statins, than current strategies to drive down cholesterol to a certain target, according to the U-M study. While study authors support the use of cholesterol-lowering statins, they conclude that patients and their doctors should consider all the factors that put them at risk for heart attack and strokes.
A new study concludes that many doctors appear to have largely ignored a Food and Drug Administration warning to screen users of new antipsychotic drugs for high blood sugar and cholesterol, which poses risks to their health and raises questions about the efficacy of warning protocols in general. The research analyzed about 109, 000 Medicaid patients taking "second generation" antipsychotic drugs, which can cause increases in blood sugar, cholesterol and significant weight gain, as well as other symptoms - significantly raising the risk of diabetes. It was done by health researchers from Oregon, Colorado, Georgia and Missouri, and just published in the Archives of General Psychiatry.
Amarin Corporation Announces First Patients Enrolled In Two Phase 3 Clinical Trials Assessing AMR101 For The Treatment Of Cardiovascular Disease
Amarin Corporation plc (Nasdaq: AMRN), a clinical-stage biopharmaceutical company focused on improving the treatment of cardiovascular disease, announced that first patients were enrolled in the MARINE and ANCHOR Phase 3 clinical trials for AMR101, the Company's lead product candidate. These clinical trials are designed to demonstrate that AMR101 lowers triglyceride levels in patients with very high triglycerides (the MARINE Study) and high triglycerides in patients with mixed dyslipidemia being treated with statins (the ANCHOR Study). It is estimated that over 27 million people in the US have elevated triglyceride levels which are associated with the increased risk of developing coronary artery disease as well as being a component of certain other metabolic disorders, such as diabetes and obesity.